Neal Shore, MD, FACS, presents the case of a 74-year-old man with metastatic castration-resistant prostate cancer (mCRPC) and discusses the factors that influence treatment selection for patients with the disease.
EP. 1: Case Presentation: A 74-Year-Old Man With Metastatic Prostate Cancer
Neal Shore, MD, FACS, presents the case of a 74-year-old man diagnosed with metastatic prostate cancer.
EP. 2: Available Treatment Options for Metastatic Castration-Resistant Prostate Cancer (mCRPC) After Docetaxel and AR-Targeted Therapy
Dr Shore reviews the available treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC), visceral disease, and no actionable genomic alterations, who received prior treatment with docetaxel and AR-targeted therapy.
EP. 3: Cabazitaxel for the Treatment of mCRPC: Data From the PROSELICA and FIRSTANA Trials
Neal Shore, MD, FACS, discusses data from the PROSELICA and FIRSTANA trials investigating cabazitaxel for the treatment of mCRPC, including a look at the post-hoc analyses of PROSELICA.
EP. 4: Cabazitaxel for the Treatment of mCRPC: Data From the CARD Trial
Dr Shore continues his review of data on cabazitaxel for the treatment of mCRPC by highlighting efficacy data from the CARD trial and real-world data that could impact practice.
EP. 5: Factors for Consideration When Selecting Patients with mCRPC for Treatment With Cabazitaxel
Neal Shore, MD, FACS, explains the treatment regimen he would have chosen for the patient with mCRPC in the presented case, and what factors he uses to inform treatment decision-making.
EP. 6: Selecting Between Treatment With Cabazitaxel or Radiotherapy for Patients with mCRPC
Dr Shore details how he approaches treatment selection between cabazitaxel and radiotherapy for patients with mCRPC.
EP. 7: The Evolution of AR Pathway Inhibitors and Docetaxel Utilization in mCRPC Treatment and the Impact on Cabazitaxel
Neal Shore, MD, FACS, speculates on how the utilization of AR-pathway inhibitors and docetaxel in earlier lines of mCRPC treatment has also influenced treatment with cabazitaxel.
EP. 8: Unmet Needs and Clinical Pearls in mCRPC
Dr Shore closes his discussion by highlighting remaining unmet needs in mCRPC treatment and providing advice for community oncologists.
2 Clarke Drive Cranbury, NJ 08512